Weight & metabolic
CagriSema
Cagrilintide + Semaglutide Combination
A fixed-dose combination of two peptides — cagrilintide (an amylin analog) and semaglutide (GLP-1 agonist). Targets two different hunger pathways for enhanced weight loss beyond either drug alone.
Also known as: Cagrilintide + Semaglutide, cagri-sema
- Status
- CagriSema is submitted to the FDA for approval but not yet approved.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- ~7 days (combined formulation)
- How it's taken
- Weekly subcutaneous injection
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- GLP-1, Amylin
How CagriSema works
Cagrilintide mimics amylin, a hormone released with insulin after meals that promotes fullness and slows digestion. Combined with semaglutide's GLP-1 effects, it creates a more complete appetite suppression through two complementary brain pathways.
What research has looked at
- ~20.4% weight loss in REDEFINE-1 trial
- Two complementary mechanisms of action
- May work for patients who plateau on GLP-1 alone
- Single weekly injection for both compounds
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Nausea (common early on)
- Vomiting
- Diarrhea
- Constipation
- Fatigue
- Injection site reactions
Sources
- Active clinical trials for cagrisema cagrilintide semaglutide · U.S. National Library of Medicine
- PubMed research on cagrilintide semaglutide REDEFINE · NIH · National Library of Medicine
- DrugBank record for cagrilintide · DrugBank
Track CagriSema in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
CagriSema FAQ
What is CagriSema?
A fixed-dose combination of two peptides — cagrilintide (an amylin analog) and semaglutide (GLP-1 agonist). Targets two different hunger pathways for enhanced weight loss beyond either drug alone.
How does CagriSema work?
Cagrilintide mimics amylin, a hormone released with insulin after meals that promotes fullness and slows digestion. Combined with semaglutide's GLP-1 effects, it creates a more complete appetite suppression through two complementary brain pathways.
Is CagriSema FDA approved?
No. CagriSema is submitted to the FDA for approval but not yet approved. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of CagriSema?
Reported half-life: ~7 days (combined formulation).
How is CagriSema taken?
Weekly subcutaneous injection.
What side effects have been reported with CagriSema?
Reported in the sources: Nausea (common early on); Vomiting; Diarrhea; Constipation; Fatigue; Injection site reactions.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.